Balaji Amines 36th Annual General Meeting will be on July 11

Balaji Amines Limited has announced that its 36th Annual General Meeting (AGM) is scheduled to take place on Thursday, July 11, 2024, at 12:00 Noon IST. Due to current circumstances, the meeting will be conducted via Video Conference (VC) or Other Audio-Visual Means (OAVM).

The AGM aims to address several crucial agenda items that include the adoption of Audited Financial Statements for the fiscal year ended March 31, 2024, along with the Auditors' and Directors' reports.

Ordinary Business:

1. Receive and adopt the Audited Financial Statements, including Audited Consolidated Financial Statements, for the Financial Year ended March 31, 2024, along with the Reports of the Board of Directors and Auditors.
2. Declare a dividend of Rs11 per Equity Share for the Financial Year 2023-24.
3. Appoint a Director in place of Mr. Dundurapu Ram Reddy (DIN: 00003864), who retires by rotation and offers himself for re-appointment.

Special Business: 

Ratify the remuneration payable to Mr. Narayan D. Dontul, Cost Accountants, Solapur (Firm Registration Number: 100224), appointed as Cost Auditors to audit the cost records of the company for the Financial Year ended March 31, 2025. The remuneration amounts to C75,000/- (plus GST and reimbursement of out-of-pocket expenses).

• This resolution authorizes the Board of Directors to take necessary actions, seek approvals, and resolve any related issues to implement this decision effectively.

36th Annual Report of Balaji Amines 

Balaji Amines Limited, a prominent manufacturer established in 1988, has released its 36th Annual Report, showcasing its robust growth and strategic initiatives in the chemical and energy sectors. The company specializes in producing Aliphatic Amines, Derivatives, Speciality Chemicals, and Pharma Excipients, catering to diverse industries including pharmaceuticals and pesticides.

Key Highlights:

1. New Investments: The company reported significant investments totaling Rs250 crore towards enhancing India's self-sufficiency in chemicals and energy. This includes setting up a state-of-the-art 100,000 TPA DME manufacturing facility, aimed at replacing imported LPG in industrial and aerosol applications.
2. Expansion Projects: Balaji Amines is expanding its production capabilities with new plants for Methylamines, Electronic Grade DMC, N-Methylmorpholine (NMM), and N-(N-Butyl) Thiosphoric Triamide (NBPT). These initiatives align with the government's vision of Atmanirbhar Bharat and Make in India.
3. Environmental Initiatives: In line with ESG compliance, the company has initiated a Solar Power Plant with an initial capacity of 8 MW, aimed at reducing carbon footprint across its operations.
4. Future Outlook: The company anticipates substantial revenue growth, projected to reach Rs 3,000 to 4,000 crore in the next 2 to 3 years upon full operationalization of its new facilities.

Financial outlook data

For more detailed insights into Balaji Amines' achievements and future plans, refer to their 36th Annual Report by clicking on this link.

Balaji Amines  

Balaji Amines Limited, established in 1988, holds a prominent position in India as a leading manufacturer of Aliphatic Amines, their Derivatives, Speciality Chemicals, and Pharma Excipients. Operating from state-of-the-art facilities in Maharashtra and Telangana, the company produces over 40 products for diverse industries including pharmaceuticals and pesticides.

With a strong emphasis on innovation, supported by sophisticated R&D laboratories, Balaji Amines maintains enduring relationships with major clients both domestically and internationally. Its global footprint spans across more than 50 countries, exporting products to key markets such as the U.S., UK, Australia, and various nations across Europe, Asia, and Africa.